Pulmonary vasculitis

European Respiratory Monograph

Volumn 5, Issue 14, 2000, Pages 226-243

  Cordier, J F ^a  

^a UNIVERSITÉ LYON 1   (France)

Author keywords

Churg Strauss syndrome; Microscopic polyangiitis; Pulmonary vasculitis; Wegener's granulomatosis

Indexed keywords

ANTIBIOTIC AGENT; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; ETOPOSIDE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MONOCLONAL ANTIBODY; PENTAMIDINE;

BLADDER CANCER; CHURG STRAUSS SYNDROME; CLINICAL FEATURE; CYSTITIS; DIAGNOSTIC IMAGING; DISEASE CLASSIFICATION; DRUG INDUCED DISEASE; FIBEROPTIC BRONCHOSCOPY; HUMAN; LUNG DISEASE; LUNG LAVAGE; PNEUMONIA; PROGNOSIS; REVIEW; VASCULITIS; WEGENER GRANULOMATOSIS;

EID: 0033821125     PISSN: 1025448X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (179)

1. The American College of rheumatology 1990 criteria for the classification of vasculitis
2. Limitations of the 1990 American College of Rheumatology classification criteria in the diagnosis of vasculitis
3. Nomenclature of systemic vasculitides. Proposal of an international consensus conference
4. Clinical and pathological classification of ANCA-associated vasculitis: What are the controversies?
5. Nomenclature and classification of vasculitis: Plus ca change, plus c'est la meme chose
6. Autoantibodies against neutrophils and monocytes: Tool for diagnosis and marker of disease activity in Wegener's granulomatosis
7. How to test for antineutrophil cytoplasmic antibodies evidence based immunology?
8. Diagnostic value of classical and atypical antineutrophil cytoplasmic antibody (ANCA) immunofluorescence patterns
9. Clinical spectrum associated with positive ANCA titres in 94 consecutive patients: Is there a relation with PR-3 negative c-ANCA and hyper-gammaglobulinemia
10. Clinical relevance of testing for antineutrophil cytoplasm antibodies (ANCA) with a standard indirect immunofluorescence ANCA test in patients with upper or lower respiratory tract symptoms
11. A review of immunofluorescent patterns associated with antineutrophil cytoplasmic antibodies (ANCA) and their differentiation from other antibodies
12. Clinical spectrum associated with ANCA of defined antigen specificities in 98 selected patients
13. Lesions of the respiratory tract associated with the finding of antineutrophil cytoplasmic autoantibodies with a perinuclear staining pattern
14. Anticytoplasmic autoantibodies in the diagnosis and follow-up of Wegener's granulomatosis
15. Anticytoplasmic autoantibodies: Their immunodiagnostic value in Wegener's granulomatosis
16. Association of autoantibodies to myeloperoxidase with different different forms of vasculitis
17. The role of antineutrophil cytoplasmic antibody (c-ANCA) testing in the diagnosis of Wegener's granulomatosis. A literature review and meta-analysis
18. A prospective study of antineutrophil cytoplasmic antibody (c-ANCA) and clinical criteria in diagnosing Wegener's granulomatosis
19. Antineutrophil cytoplasmic antibodies as markers for systemic autoimmune disease
20. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis
21. Diagnostic predictive value of ANCA serology
22. Epidemiology of systemic vasculitis: Changing incidence or definition?
23. The epidemiology of Wegener's granulomatosis
24. Bronchiolitis obliterans-organizing pneumonia (BOOP)-like variant of Wegener's granulomatosis. A clinicopathologic study of 16 cases
25. Wegener's granulomatosis: Histological documentation of common and uncommon manifestations in 216 patients
26. Solitary lung lesions in Wegener's granulomatosis. Pathologic findings and clinical significance in 25 cases
27. The eosinophilic variant of Wegener's granulomatosis
28. Wegener's granulomatosis
29. Wegener's granulomatosis in the 1990s - A pulmonary pathologist's perspective
30. The pulmonary biopsy in the early diagnosis of Wegener's (pathergic) granulomatosis: A study based on 35 open lung biopsies
31. Surgical pathology of the lung in Wegener's granulomatosis. Review of 87 open lung biopsies from 67 patients
32. Pulmonary lesions in Wegener's granulomatosis: A clinicopathologic study of 22 autopsy cases
33. Les lesions pulmonaires de la maladie de Wegener. Rapport du groupe francais de recherche anatomo-clinique. Etude de 40 biopsies pulmonaires
34. Bronchocentric injury in Wegener's granulomatosis: A report of five cases
35. A morphologic and immunohistologic study of the evolution of the necrotizing palisading granuloma of pathergic (Wegener's) granulomatosis
36. La granulomatose de Wegener. Etude anatomoclinique. Revue de la litterature
37. Pulmonary Wegener's granulomatosis. A clinical and imaging study of 77 cases
38. Wegener granulomatosis: An analysis of 158 patients
39. Granulomatose de Wegener. Aspects cliniques, problemes nosologiques. Revue de la litterature a propos de 30 observations
40. Wegener's granulomatosis: Prospective clinical and therapeutic experience with 85 patients for 21 years
41. Wegener's granulomatosis: Studies in eighteen patients and a review of the literature
42. Wegener's granulomatosis
43. Wegener's granulomatosis. Anatomic correlates, a proposed classification
44. Wegener's granuloma. A series of 26s British cases seen between 1975 and 1985. A report by a sub-committee of the British Thoracic Society Research Committee. Q J Med
45. Giant cell granuloma of the respiratory tract (Wegener's granulomatosis)
46. Unilateral diffuse pulmonary artery involvement in Takayasu's arteritis associated with coronary-pulmonary artery fistula and bronchopulmonary artery fistula: A case report
47. Wegener's granulomatosis upper respiratory tract and pulmonary radiographic manifestations in 30 cases with pathogenetic consideration
48. Pulmonary Wegener's granulomatosis changes at follow-up CT
49. Imaging of thoracic Wegener's granulomatosis: The computed tomographic appearance
50. Pulmonary Wegener's granulomatosis. Correlation between high-resolution CT findings and clinical scoring of disease activity
51. Wegener granulomatosis: CT features of parenchymal lung disease
52. Computed tomography of the lung in Wegener's granulomatosis
53. Radiographic course of pulmonary manifestations in Wegener's granulomatosis under immunosuppressive therapy
54. Thoracic manifestations of Wegener granulomatosis: Diagnosis and course
55. Unusual radiographic features of Wegener's granulomatosis
56. Wegener's granulomatosis: A radiological review of the pulmonary manifestations at initial presentation and during relapse
57. Tracheobronchial involvement in Wegener's granulomatosis
58. Wegener's granulomatosis of the subglottis and the upper portion of the trachea
59. Clinical features and therapeutic management of subglottic stenosis in patients with Wegener's granulomatosis
60. The management of subglottic stenosis in patients with Wegener's granulomatosis
61. Subglottic stenosis complicating Wegener's granulomatosis: Surgical repair as a viable treatment option
62. Bronchoalveolar lavage analysis in Wegener's granulomatosis. A method to study disease pathogenesis
63. Bronchoalveolar lavage cell profiles in Wegener's granulomatosis
64. Idiotypic induction of autoimmunity: A new classification of autoimmune diseases
65. Acute fulminant Wegener granulomatosis
66. Diffuse pulmonary hemorrhage in Wegener's granulomatosis
67. Wegener's granulomatosis presenting with massive pulmonary hemorrhage and capillaritis
68. Diffuse pulmonary hemorrhage. An uncommon manifestation of Wegener's granulomatosis
69. Wegener's granulomatosis presenting as acute respiratory failure with anti-neutrophil-cytoplasm antibodies
70. Hemorragies intra-alveolaires de la granulomatose de Wegener. Etude retrospective de 9 cas
71. Pulmonary haemorrhage complicating Wegener's granulomatosis and microscopic polyarteritis
72. Ear, nose and throat manifestations in c-ANCA-positive vasculitides. Diagnostic, therapeutic and pathogenic implications
73. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis
74. Efficacy of transbronchial biopsy in pulmonary vasculitides
75. Antineutrophil cytoplasmic antibodies in Wegener's granulomatosis
76. Serial measurements of antineutrophil cytoplasmic autoantibodies in patients with systemic vasculitis
77. Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with Wegener's granulomatosis
78. Rise in ANCA titer: To treat or not to treat?
79. ANCA and predicting relapse in systemic vasculitis
80. Wegener granulomatosis
81. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis
82. Cyclophosdphamide-induced bladder toxicity in Wegener's granulomatosis
83. Pneumocystis carinii pneumonia: A major complication of immunosuppressive therapy in patients with Wegener's granulomatosis
84. Factors associated with pneumocystis carinii pneumonia in Wegener's granulomatosis
85. Treatment of Wegener's granulomatosis with sulfamethoxazole-trimethoprim
86. Wegener's granulomatosis: Observations on treatment with antimicrobial agents
87. Wegener granulomatosis and trimethoprim-sulfamethoxazole. Complete remission after a twenty-year course
88. Sulfamethoxazole-trimethoprin therapy for Wegener's granulomatosis
89. Long-term sulfamethoxazole-trimethoprim in Wegener's granulomatosis
90. Response to trimethoprim/sulfamethoxazole in Wegener's granulomatosis depends on the phase of disease
91. Trimethoprim-sulfamethoxazole for scleritis associated with limited Wegener's granulomatosis: Use of histopathology and anti-neutrophil cytoplasmic antibody (ANCA) test
92. Traitement par le cotrimoxazole de la granulomatose de Wegener (7 observations)
93. The treatment of Wegener's granulomatosis with trimethoprim/sulfamethoxazole: Illusion or vision?
94. Trimethoprim-sulfamethoxazole (cotrimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group
95. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis
96. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: A prospective, randomized study
97. Wegener's granulomatosis: Long-term follow-up of patients treated with pulse cyclophosphamide
98. Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis
99. The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate
100. Induction of remission in Wegener's granulomatosis with low dose methotrexate
101. Wegener's granulomatosis
102. Necrotizing alveolar capillaritis in autopsy cases of microscopic polyangiitis. Incidence, histopathogenesis, and relationship with systemic vasculitis
103. Small-vessel vasculitis
104. Polyarteritis and the kidney
105. Vasculitis affecting the kidney: Presentation, histopathology and long-term outcome
106. Microscopic polyarteritis: Presentation, pathology and prognosis
107. Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis
108. Microscopic polyangiitis. Clinical and laboratory findings in eighty-five patients
109. Pulmonary-renal syndrome with 'triad' involvement due to small vessel vasculitis
110. Respiratory failure in ANCA-associated vasculitis
111. Microscopic polyarteritis has a poor prognosis in chinese
112. Microscopic polyangiitis with alveolar hemorrhage. A study of 29 cases and a review of the literature
113. Six cases of microscopic polyarteritis exhibiting acute interstitial pneumonia
114. Progressive obstructive lung disease associated with microscopic polyangiitis
115. Pulmonary capillaritis. The association with progressive irreversible airflow limitation and hyperinflation
116. Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis
117. The syndrome of lung hemorrhage and nephritis is usually an ANCA-associated condition
118. Case Records of the Massachusetts General Hospital. Case 52-1993
119. Anti-neutrophil cytoplasm antibodies and anti-glomerular basement membrane antibodies: Two coexisting distinct autoreactivities detectable in patients with rapidly progressive glomerulonephritis
120. Pulmonary vasculitis
121. Antimyeloperoxidase autoantibody-associated necrotizing alveolar capillaritis
122. Antineutrophil cytoplasmic autoantibody-associated alveolar capillaritis in patients presenting with pulmonary hemorrhage
123. Diffuse alveolar hemorrhage with underlying isolated, pauciimmune pulmonary capillaritis
124. Pulmonary haemorrhage in Henoch-Schonlein purpura
125. Diffuse intrapulmonary hemorrhage and renal failure in adult Hemoch-Schonlein purpura
126. Fatal pulmonary Henoch-Schonlein syndrome
127. Pulmonary disease with hemorrhage in Henoch-Schoenlein purpura
128. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa
129. Systemic vasculitis with asthma and eosinophilia: A clinical approach to the Churg-Strauss syndrome
130. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients
131. Churg-Strauss syndrome in a district hospital
132. Allergic granulomatosis and angiitis (Churg-Strauss syndrome). Report and analysis of 30 cases
133. Manifestations systemiques d'angeite avec asthme et hypereosinophilie. Etude de 10 observations
134. L'angeite allergique avec granulomatose: Syndrome de Churg et Strauss. Etude retrospective de 16 observations
135. Churg-Strauss syndrome
136. Churg-Strauss syndrome associated with zafirlukast
137. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast
138. Churg-Strauss syndrome after zafirlukast in two patients not receiving systemic steroid treatment
139. Churg-Strauss syndrome after corticosteroid withdrawal in an asthmatic patient treated with pranlukast
140. Churg-Strauss syndrome: The spectrum of pulmonary CT findings in 17 patients
141. Bronchoalveolar lavage in allergic granulomatosis and angiitis
142. Evolution to dilated cardiomyopathy from acute eosinophilic pancarditis in Churg-Strauss syndrome
143. Cardiac manifestations of Churg-Strauss syndrome: Report of a case and review of the literature
144. Necrotizing myocardial vasculitis in Churg-Strauss syndrome. Clinicohistologic evaluation of steroids and immunosuppressive therapy
145. The Churg-Strauss syndrome. A case report with angiographically documented coronary involvement and a review of the literature
146. Heart transplantation for Churg-Strauss syndrome
147. Recurrence of Churg Strauss vasculitis in a transplanted heart
148. Formes frustes of Churg-Strauss syndrome
149. Pulmonary arterial aneurysms in Behcet's syndrome: A report of 24 cases
150. Pulmonary disease in Behcet's syndrome
151. Thoracic involvement in Behcet's disease: Pathologic, clinical, and imaging features
152. Pulmonary vasculitis in Behcet's disease
153. Thoraeic manifestations of Behcet syndrome: Radiographie and CT findings in nine patients
154. Behcet disease: Pulmonary arterial involvement in 15 cases
155. Pulmonary artery disease in Takayasu's arteritis: Angio-graphic findings
156. Pulmonary artery involvement in Takayasu's arteritis
157. The incidence and patterns of pulmonary artery involvement in Takayasu's arteritis
158. Pulmonary artery involvement as first manifestation in three cases of Takayasu arteritis
159. Takayasu's disease causing pulmonary hypertension and right heart failure
160. Large vessel pulmonary arteritis mimicking chronic thromboembolic disease
161. Respiratory tract symptoms as a clue to giant cell arteritis
162. Giant cell arteritis manifesting as chronic cough and fever of unknown origin
163. Pleural effusion as manifestation of temporal arteritis
164. Giant cell arteritis with pulmonary nodules
165. The lung in polyarteritis nodosa: A pathologic study of 10 cases
166. Hypoeomplementemic urticarial vasculitis syndrome responsive to dapsone
167. Pulmonary disease in idiopathic urticarial vaseulitis
168. Hypocomplementemic urticarial vasculitis. Association with chronic obstructive pulmonary disease
169. Hypocomplementemic urticarial vasculitis syndrome. Clinical and serologic findings in 18 patients
170. Urticarial vasculitis: A histopathologic and clinical review of 72 cases
171. Pulmonary vasculitis and rheumatic diseases
172. Microangiitis in lupus-induced pulmonary hemorrhage
173. A lung biopsy is unnecessary in the management of ANCA-positive patients with chestroentgenographic abnormalities
174. The role of superantigens in vasculitis
175. Molecular approaches for identification of infectious agents in Wegener's granulomatosis and other vasculitides
176. Pathogenesis of Wegener's granulomatosis
177. Immunodiagnostic and pathophysiologic aspects of antineutrophil cytoplasmic antibodies in vasculitis
178. Immunopathogenesis of vasculitis
179. The patient with vasculitis